Dr. Michael Fehlings obtained his MD and PhD from the University of Toronto (UofT). He is a Staff Neurosurgeon at Toronto Western Hospital and Senior Scientist at the Krembil Research Institute, which is part of the University Health Network, Vice Chair of Research in the Department of Surgery at UofT and Co-Director of the UofT Spine Program. He has received numerous awards including the Olivecrona Award, the Henry Farfan Award and the Richard H. Winn prize. Dr. Fehlings is a Fellow of the Canadian Academy of Health Sciences and the Royal Society of Canada.

Dr. Hofstein came to Toronto from Israel in 2009 to assume the position of President & CEO MaRS Innovation (recently renamed as Toronto Innovation Acceleration Partners, TIAP). At this position, Dr. Hofstein led the creation of over fifty start-up companies primarily in the healthcare space. Among the companies of primary note are Triphase, Fibrocor and Notch Therapeutics, in which Dr. Hofstein has been a cofounder and a director. In addition, Dr. Hofstein is a member of the board of several not-for-profit organizations in Quebec and Ontario.

Dr. Paul Bradshaw obtained his PhD from the Institute of Cancer Research (ICR) at the Royal Cancer (Marsden) Hospital, University of London, UK and his MBA from the Kellogg Schulich global executive MBA program. He undertook post-doctoral studies in the Program of Genetics and Genome Biology at the Hospital for Sick Children, Toronto, Canada before moving to the Department of Genetics and Development in the Krembil Research Institute at the University Health Network (UHN).

Dr. Christopher Ahuja obtained his MD from Queen's University, Canada and is completing his residency training in Neurosurgery at the University of Toronto. He is currently a member of the Surgeon-Scientist Training Program at the University of Toronto where he is specialises in developing translationally-relevant bioengineered human stem cell therapies for spinal cord injury.  Dr. Ahuja joined Inteligex in 2018 where he leads translational research and development of the cell therapy pipeline.

Dr. Mamad Khazaei is the head of stem cell biology, differentiation, as well as cell and GMP manufacturing operations. He joined Inteligex in 2018 where his research is focused on the discovery, development, and delivery of innovative neural stem cells and next-generation cell therapy products. Trained as a cell biologist and inspired by transforming patients' lives, his research has enabled Inteligex to create a leadership position in neural stem cell programs, which offer hope for safe and effective treatments for neurodegenerative diseases including spinal cord injury, multiple sclerosis, and cerebral palsy.

Dr. Tim Worden holds a PhD in biomechanics from the University of Guelph, where he studied the effects of perception and training on human locomotion in complex environments. He has expertise in scientific communication and has been the Editorial Coordinator for Dr. Fehlings’ research team at the Krembil Research Institute since 2017. Dr. Worden joined Inteligex in 2020 as the Director of Communications.